Screenshot-199
Hot topics
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
Who Is Monitoring Quality in India’s Small Drug Units?
The Telangana Drugs Control Administration’s stop-use notice on a...
Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma
https://www.pharmamanufacturing.com/articles/2011/095
A quiet but seismic shift is underway in global...
Partner Don’t Punish
Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta
Can Indian Doctors and Patients Trust Generics Over Branded Generics? ...
The ongoing debate around branded versus generic medicines in...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
Hot topics
Indian Pharma Competitor Analysis – Jan 2025
Competitor Analysis – Indian Pharma Market Jan 2025
This analysis...
Violence Against Doctors: Doctor-Patient Relationship Bruised and Battered
If a business fails, it was an idea that didn’t work. If treatment fails – it must be a botch up. A broken gadget may be beyond repair, but not a patient in a doctor’s hands. From such ungraded expectations stems the potential for things to take an ugly turn.
An unwanted profession dealing with an unwanted condition, namely Ill health:
If possible, we would wish away death and diseases, hospitals and doctors. A hospital is not a holiday resort, but it too costs money. And the scenario of an adverse outcome like death simply becomes unacceptable.
A Social Experiment
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, RB Balakrishna and Rajiv Jayaraman
Biocon Bats for Affordable Insulin and Ozempic
🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...
MedicinMan Steps into Year Five
Articles by K. Hariram, Daxesh Patel, Gopal Kishore, Amit Jain, Sunil Bajaj and Vivek Hattangadi
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Newsletter
Get important news delivered directly to your inbox and stay connected!